Status

Recruiting now clinical trials

Studies whose latest retrieved public registry status is Recruiting now.

1,541active studies

1,541recruiting now

75countries represented

838largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

Atherosclerosis Cardiovascular Disease, Chronic Kidney DiseaseCondition

Orforglipron, PlaceboTreatment

Argentina566 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07241390See eligibility →

Recruiting nowPhase 3

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

Metabolic Dysfunction-Associated Steatotic Liver DiseaseCondition

Tirzepatide, RetatrutideTreatment

Argentina, Australia563 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07165028See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Overweight, ObesityCondition

Eloralintide, PlaceboTreatment

Australia, Belgium187 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07392190See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

Peripheral Arterial DiseaseCondition

Orforglipron, PlaceboTreatment

Argentina, Australia161 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07223593See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Overweight, ObesityCondition

Eloralintide, PlaceboTreatment

Argentina, China157 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07282600See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

Osteoarthritis, Overweight or ObesityCondition

Eloralintide, PlaceboTreatment

Argentina, Belgium152 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07353931See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

Urinary Incontinence,StressCondition

Orforglipron, PlaceboTreatment

Canada, China136 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07202884See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Sleep Apnea, Obstructive, ObesityCondition

Eloralintide, PlaceboTreatment

Australia, Brazil115 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07369011See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

OsteoarthritisCondition

Orforglipron, PlaceboTreatment

Canada, China88 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07153471See eligibility →

Recruiting nowPhase 2

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Obesity, OverweightCondition

LY3305677, LY3841136Treatment

Argentina, United States56 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT06143956See eligibility →

Recruiting nowPhase 4

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

Psoriatic Arthritis, Overweight or ObesityCondition

TirzepatideTreatment

Puerto Rico, United States55 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT06864026See eligibility →

Recruiting nowPhase 2

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Obesity, OverweightCondition

Macupatide, EloralintideTreatment

Argentina, Australia42 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07215559See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting

Diabetes Mellitus, Type 2, Diabetes MelletusCondition

OrforglipronTreatment

India, Saudi Arabia40 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07613307See eligibility →

Recruiting nowNot applicable

Multi-Modal Digital Interventions for Adolescent Weight Management

Obesity, Adolescent, Weight Change, BodyCondition

Multi-Modal Digital InterventionTreatment

Taiwan2 locations

National Yang Ming Chiao Tung UniversitySponsor

Updated 2026-09-08 · NCT06920862See eligibility →

Recruiting nowNot applicable

Inflammation, Diabetes, Ethnicity and Obesity Cohort

Obesity, Diabetes MellitusCondition

Intervention not listedTreatment

United States1 locations

University of California, San FranciscoSponsor

Updated 2026-09-08 · NCT03022682See eligibility →

Recruiting nowNot applicable

tDCS With Cognitive Training to Reduce Impulsivity and Weight in Veterans With Obesity

ObesityCondition

Sham Transcranial Direct Current Stimulation (tDCS), Active Transcranial Direct Current Stimulation (tDCS)Treatment

United States1 locations

VA Office of Research and DevelopmentSponsor

Updated 2026-09-08 · NCT05225233See eligibility →

Recruiting nowPhase 1

Graded Insulin Suppression Test P&F

Insulin Resistance, HyperinsulinemiaCondition

Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia), Insulin regular, 32 mU/m2/min (hyperinsulinemia)Treatment

United States1 locations

Columbia UniversitySponsor

Updated 2026-09-08 · NCT06592261See eligibility →

Recruiting nowNot applicable

Therapeutic Potential of a Synbiotic to Improve Mental Health in Subjects With Obesity.

Obese Patients (BMI ≥ 30 kg/m²), AnxietyCondition

Synbiotic, PlaceboTreatment

Spain1 locations

Celia BañulsSponsor

Updated 2026-09-08 · NCT06901739See eligibility →

Recruiting nowPhase 3

Semaglutide for Smoking Cessation in Patients With Diabetes

Diabetes Mellitus, Type 2, Nicotine AddictionCondition

Semaglutide, Nicotine replacementTreatment

Canada1 locations

Ottawa Heart Institute Research CorporationSponsor

Updated 2026-09-08 · NCT07059377See eligibility →

Recruiting nowNot applicable

Impact of Overweight, Obesity, and Lifestyle Changes on Work Performance and Well-Being in Medical Residents

Obesity, OverweightCondition

Obesity and Overweight Status, No Intervention (Observational Assessment)Treatment

Italy1 locations

Fondazione Policlinico Universitario Agostino Gemelli IRCCSSponsor

Updated 2026-09-08 · NCT07677800See eligibility →

Recruiting nowPhase 1

Phase 1 Clinical Study of MWN105 Injection in Participants With Overweight or Obesity

Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)Condition

MWN105 1, MWN105 2Treatment

China1 locations

Shanghai Minwei Biotechnology Co., LtdSponsor

Updated 2026-09-08 · NCT07803809See eligibility →

Recruiting nowNot applicable

Effects of Dietary Supplements on Muscle Mass and Function While Using GLP-1 Medication

Obesity & Overweight, Muscle Mass and StrengthCondition

Whey Protein Supplementation, Maltodextrin Placebo CapsulesTreatment

United States1 locations

University of California, Los AngelesSponsor

Updated 2026-09-08 · NCT07806838See eligibility →

Recruiting nowPhase 3

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Ulcerative Colitis, Obesity or OverweightCondition

Mirikizumab, MirikizumabTreatment

Austria, Belgium187 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06937086See eligibility →

Recruiting nowPhase 3

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Crohn's Disease, Obesity or OverweightCondition

Mirikizumab, MirikizumabTreatment

Austria, Belgium183 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06937099See eligibility →

Recruiting nowPhase 3

AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

Diabetes Mellitus, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Argentina, Brazil74 locations

Novo Nordisk A/SSponsor

Updated 2026-09-04 · NCT07533175See eligibility →

Recruiting nowPhase 3

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

Obesity, Weight GainCondition

Tirzepatide, PlaceboTreatment

Argentina, Australia69 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06439277See eligibility →

Recruiting nowPhase 3

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

Obesity, Overweight and/or ObesityCondition

PF-08653944, PlaceboTreatment

Brazil, Canada50 locations

PfizerSponsor

Updated 2026-09-04 · NCT07595549See eligibility →

Recruiting nowPhase 4

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

Psoriasis, Overweight or ObesityCondition

TirzepatideTreatment

United States39 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06857942See eligibility →

Recruiting nowPhase 3

A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

Overweight, ObesityCondition

Cagrilintide, Placebo cagrilintideTreatment

Greece, Hungary36 locations

Novo Nordisk A/SSponsor

Updated 2026-09-04 · NCT07745504See eligibility →

Recruiting nowPhase 1

A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity

Overweight, ObesityCondition

NNC0721-8060, SemaglutideTreatment

United States2 locations

Novo Nordisk A/SSponsor

Updated 2026-09-04 · NCT07767175See eligibility →

Recruiting nowNot applicable

Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate

Overweight, ObesityCondition

Standard Diet, Ketogenic DietTreatment

United States1 locations

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Sponsor

Updated 2026-09-04 · NCT06044935See eligibility →

Recruiting nowEarly Phase 1

Effect of Tirzepatide on Markers of MASLD in Patients With Obesity

MASLD, ObesityCondition

TirzepatideTreatment

United States1 locations

University of New MexicoSponsor

Updated 2026-09-04 · NCT06934642See eligibility →

Recruiting nowNot applicable

This Study Will Evaluate Cardiorespiratory and Muscular Fitness to Examine Associations With Anthropometric Characteristics and Other Indicators of Cardiometabolic Risk Among Patients With or Without Autism Spectrum Disorder

Autism Spectrum Disorder (ASD), Cardiometabolic Health IndicatorsCondition

Intervention not listedTreatment

United States1 locations

University of VirginiaSponsor

Updated 2026-09-04 · NCT07804680See eligibility →

Recruiting nowPhase 3

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Atherosclerotic Cardiovascular Disease, OverweightCondition

Maridebart Cafraglutide, PlaceboTreatment

Argentina, Australia783 locations

AmgenSponsor

Updated 2026-09-03 · NCT07037433See eligibility →

Recruiting nowPhase 3

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

Metabolic Dysfunction Associated SteatohepatitisCondition

Survodutide, Placebo matching survodutideTreatment

Argentina, Australia445 locations

Boehringer IngelheimSponsor

Updated 2026-09-03 · NCT06632457See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

Obesity With Diabetes, Overweight With DiabetesCondition

Ribupatide, PlaceboTreatment

Argentina, Australia167 locations

KaileraSponsor

Updated 2026-09-03 · NCT07284901See eligibility →

Recruiting nowPhase 3

A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

Type 2 DiabetesCondition

Placebo, SurvodutideTreatment

Australia, Canada121 locations

Boehringer IngelheimSponsor

Updated 2026-09-03 · NCT07754461See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

Obesity, OverweightCondition

Ribupatide, PlaceboTreatment

Argentina, Australia104 locations

KaileraSponsor

Updated 2026-09-03 · NCT07284875See eligibility →

Recruiting nowPhase 3

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

Obesity, OverweightCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Japan87 locations

AmgenSponsor

Updated 2026-09-03 · NCT07684235See eligibility →

Recruiting nowPhase 2

A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight

Obesity, OverweightCondition

BI 3034701, Placebo matching BI 3034701Treatment

Australia, Canada54 locations

Boehringer IngelheimSponsor

Updated 2026-09-03 · NCT07662122See eligibility →

Recruiting nowPhase 2

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

ABBV-295, PlaceboTreatment

Puerto Rico, United States38 locations

AbbVieSponsor

Updated 2026-09-03 · NCT07752979See eligibility →

Recruiting nowPhase 3

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

Obesity, OverweightCondition

Maridebart Cafraglutide, PlaceboTreatment

Japan, Puerto Rico37 locations

AmgenSponsor

Updated 2026-09-03 · NCT07684144See eligibility →

Recruiting nowNot applicable

New Heart Imaging Techniques to Evaluate Possible Heart Disease

Healthy, ObesityCondition

MR Imaging Techniques - 1, MR Imaging Techniques - 2Treatment

United States1 locations

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Sponsor

Updated 2026-09-03 · NCT01399385See eligibility →

Recruiting nowNot applicable

International Rapid-onset Obesity With Hypothalamic Dysfunction, Hypoventilation & Autonomic Dysregulation (ROHHAD) Registry

ROHHAD, Rapid-Onset Obesity With Hypothalamic Dysfunction, Hypoventilation & Autonomic DysregulationCondition

ROHHADTreatment

United States1 locations

Ilya KhaytinSponsor

Updated 2026-09-03 · NCT03135730See eligibility →

Recruiting nowEarly Phase 1

Sympathetic Transduction in Obesity-associated Hypertension (OB-HTN)

Hypertension, ObesityCondition

Neuropeptide YTreatment

United States1 locations

University of Texas Southwestern Medical CenterSponsor

Updated 2026-09-03 · NCT04838678See eligibility →

Recruiting nowNot applicable

EffectiVenEss of a Rehabilitation Treatment With Nordic Walking in obEse or oveRweight Patients

Cardiovascular Diseases, Diabete Type 2Condition

Nordic Walking (NW), Standard Rehabilitation (SR)Treatment

Italy1 locations

Fondazione Don Carlo Gnocchi ETSSponsor

Updated 2026-09-03 · NCT05987410See eligibility →

Recruiting nowNot applicable

Ketogenic Diet and Diabetes Demonstration Project

Type 2 Diabetes, PreDiabetesCondition

Ketogenic diet, Low Fat dietTreatment

United States1 locations

University of New MexicoSponsor

Updated 2026-09-03 · NCT06115265See eligibility →

Recruiting nowPhase 1

A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants

Overweight, ObesityCondition

RO7795081, PlaceboTreatment

Netherlands1 locations

Hoffmann-La RocheSponsor

Updated 2026-09-03 · NCT06982131See eligibility →

Recruiting nowNot applicable

Interoception and Illness Perception Before and After Bariatric Surgery: Impact on Disordered Eating (Interoceptiv-BAR)

ObesityCondition

Intervention not listedTreatment

Italy1 locations

Fondazione Policlinico Universitario Agostino Gemelli IRCCSSponsor

Updated 2026-09-03 · NCT07594275See eligibility →

Recruiting nowPhase 1

A Study to Evaluate ALN-6222 in Participants With Obesity

ObesityCondition

ALN-6222, PlaceboTreatment

Canada1 locations

Alnylam PharmaceuticalsSponsor

Updated 2026-09-03 · NCT07624071See eligibility →

Recruiting nowPhase 1

Alpelisib Challenge Test (ACT)

Insulin Resistance, Type 2 DiabetesCondition

Alpelisib 300 mg, Alpelisib Challenge Test (ACT): Mixed Meal Tolerance Test (MMTT) after taking alpelisibTreatment

United States1 locations

Columbia UniversitySponsor

Updated 2026-09-03 · NCT07778524See eligibility →

Recruiting nowPhase 2

Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus (T2DM)Condition

MWN109 1, MWN109 2Treatment

China1 locations

Shanghai Minwei Biotechnology Co., LtdSponsor

Updated 2026-09-03 · NCT07801820See eligibility →

Recruiting nowNot applicable

Effects of Kettlebell Swing Training Combined With Breathing Exercises on Respiratory Muscle Strength and Pulmonary Function in Overweight and Obese Young Adults

Overweight and Obese, Young AdultCondition

Kettlebell swing training, ControlTreatment

Thailand1 locations

University of PhayaoSponsor

Updated 2026-09-03 · NCT07802080See eligibility →

Recruiting nowNot applicable

Evaluation of Anhedonia and Emotional Eating in Individuals Using GLP-1 Receptor Agonists

Obesity, Emotional EatingCondition

Intervention not listedTreatment

Turkey (Türkiye)1 locations

TC Erciyes UniversitySponsor

Updated 2026-09-03 · NCT07803185See eligibility →

Recruiting nowPhase 3

Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)

Dementia, Mild, Mild Cognitive ImpairmentCondition

Mazdutide, PlaceboTreatment

China8 locations

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolSponsor

Updated 2026-09-02 · NCT07083154See eligibility →

Recruiting nowPhase 1

A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Adults Living With Obesity, Compared to a Low-calorie Diet or Placebo

Overweight, ObesityCondition

NNC0487-0111, PlaceboTreatment

Denmark, Netherlands2 locations

Novo Nordisk A/SSponsor

Updated 2026-09-02 · NCT07757087See eligibility →

Recruiting nowNot applicable

Effects of Obesity in the Aged

Obesity, AgingCondition

Mechanical unloading of the Thorax using an external cuirassTreatment

United States1 locations

University of Texas Southwestern Medical CenterSponsor

Updated 2026-09-02 · NCT05028309See eligibility →

Recruiting nowPhase 2

Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)

Overweight, Overweight and ObesityCondition

Counseling, Text MessagesTreatment

United States1 locations

Memorial Sloan Kettering Cancer CenterSponsor

Updated 2026-09-02 · NCT05770570See eligibility →

Recruiting nowNot applicable

Wild Blueberries for Gut, Brain, and Heart Health in Adults With High Blood Pressure

Hypertension (Without Type 2 Diabetes Mellitus), High Blood PressureCondition

Wild Blueberry, PlaceboTreatment

United States1 locations

Georgia State UniversitySponsor

Updated 2026-09-02 · NCT06735599See eligibility →

Recruiting nowNot applicable

Wild Blueberries for Gut, Brain, and Cardiometabolic Health in Prediabetes

Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), FemaleCondition

Wild Blueberry, PlaceboTreatment

United States1 locations

Georgia State UniversitySponsor

Updated 2026-09-02 · NCT06735651See eligibility →

This page shows the first 60 studies. Use the full search to filter all matches.

Related statuses

Opening soon671 Active, not recruiting664 Invitation only133

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.